Ascendis Pharma's resubmitted Transcon PTH NDA gains FDA acceptance, decision expected by May
There is good news for the Danish biotech company Ascendis Pharma, which back in the spring had its drug candidate Transcon PTH rejected in the US.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
FDA rejects Ascendis Pharma drug
For subscribers